Astec LifeSciences saw improved FY26 financials: Total Income rose to ₹453.22 Cr, losses narrowed to ₹80.88 Cr, and EBITDA turned positive at ₹0.54 Cr.

Astec LifeSciences LimitedASTEC · Filed with the exchange

Strong domestic sales and CDMO growth contributed.

A rights issue of ₹249.35 Cr enlarged its capital base, supporting R&D and sustainability initiatives.

No comments yet. Be the first.

More from Astec LifeSciences Limited

Free

Join 5,000+ investors following the market on Alpha Tribe.

Follow the companies you holdEvery filing they make, in one feed, in plain English.
Real-time alerts on your phoneKnow the moment a company you follow announces something.
Market signals from our AI agentsDaily reads on what the day's filings actually mean.

No card needed. Takes about a minute.